Skip to main content
logo
TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.980
+0.010 (0.51%)
Oct 8, 2025, 4:00 PM EDT - Market closed

Revenue by Product

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
T Cell Receptor-engineered T Cell
2.82M
Log In
Log In
Log In
Log In
T Cell Receptor-engineered T Cell Growth
-86.62%
Log In
Log In
Log In
Log In

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
United States
2.82M
Log In
Log In
Log In
Log In
United States Growth
-86.62%
Log In
Log In
Log In
Log In